Yan Zhou1, Benjamin I Schwartz2, Joanna Giza3, Steven S Gross2, Francis S Lee2,3, Mary Jeanne Kreek4. 1. Laboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA. zhouya@rockefeller.edu. 2. Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA. 3. Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA. 4. Laboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA.
Abstract
BACKGROUND: Anandamide (AEA)-dependent signaling is regulated by the catabolic enzyme fatty acid amide hydrolase (FAAH). Several lines of evidence have demonstrated that FAAH and AEA are involved in the behavioral effects of alcohol. Therefore, we investigated whether a selective FAAH inhibitor, URB597 (cyclohexylcarbamic acid 3'-[aminocarbonyl]-[1,1'-biphenyl]-3-yl ester), altered alcohol intake in mice in a voluntary alcohol drinking model. METHODS: Mice, subjected to 3 weeks of chronic intermittent access (IA) in a two-bottle choice paradigm with 24-h access every other day, developed rapid escalation of alcohol intake and high preference. We evaluated the pharmacological effects of URB597 after both acute (1-day) withdrawal from chronic IA and 1-week withdrawal using the alcohol deprivation effect (ADE) model. AEA and N-acyl ethanolamide (NAE) abundances were determined after chronic IA, acute (1-day), or long-term (1 and 2 weeks) withdrawal in four brain regions. RESULTS: Acute pretreatment with URB597 reduced alcohol intake and preference after acute withdrawal. This effect was blocked by pretreatment with a selective type 1 cannabinoid receptor (CB1) antagonist, suggesting a CB1-mediated mechanism. Both single- and multiple-dosing regimens with an effective dose of URB597 prevented the ADE, with no tolerance development after the multi-dosing regimen. AEA and NAE levels were transiently increased in all brain regions measured after acute withdrawal, indicating that the endocannabinoid system is involved in acute alcohol withdrawal stress response. CONCLUSION: FAAH inhibitors reduce alcohol escalation and "relapse" drinking in mice.
BACKGROUND:Anandamide (AEA)-dependent signaling is regulated by the catabolic enzyme fatty acidamide hydrolase (FAAH). Several lines of evidence have demonstrated that FAAH and AEA are involved in the behavioral effects of alcohol. Therefore, we investigated whether a selective FAAH inhibitor, URB597 (cyclohexylcarbamic acid 3'-[aminocarbonyl]-[1,1'-biphenyl]-3-yl ester), altered alcohol intake in mice in a voluntary alcohol drinking model. METHODS:Mice, subjected to 3 weeks of chronic intermittent access (IA) in a two-bottle choice paradigm with 24-h access every other day, developed rapid escalation of alcohol intake and high preference. We evaluated the pharmacological effects of URB597 after both acute (1-day) withdrawal from chronic IA and 1-week withdrawal using the alcohol deprivation effect (ADE) model. AEA and N-acyl ethanolamide (NAE) abundances were determined after chronic IA, acute (1-day), or long-term (1 and 2 weeks) withdrawal in four brain regions. RESULTS: Acute pretreatment with URB597 reduced alcohol intake and preference after acute withdrawal. This effect was blocked by pretreatment with a selective type 1 cannabinoid receptor (CB1) antagonist, suggesting a CB1-mediated mechanism. Both single- and multiple-dosing regimens with an effective dose of URB597 prevented the ADE, with no tolerance development after the multi-dosing regimen. AEA and NAE levels were transiently increased in all brain regions measured after acute withdrawal, indicating that the endocannabinoid system is involved in acute alcohol withdrawal stress response. CONCLUSION:FAAH inhibitors reduce alcohol escalation and "relapse" drinking in mice.
Authors: Antonia Serrano; Patricia Rivera; Francisco J Pavon; Juan Decara; Juan Suárez; Fernando Rodriguez de Fonseca; Loren H Parsons Journal: Alcohol Clin Exp Res Date: 2011-12-05 Impact factor: 3.455
Authors: B F Cravatt; K Demarest; M P Patricelli; M H Bracey; D K Giang; B R Martin; A H Lichtman Journal: Proc Natl Acad Sci U S A Date: 2001-07-24 Impact factor: 11.205
Authors: Francisco J Pavón; Antonia Serrano; David G Stouffer; Ilham Polis; Marisa Roberto; Benjamin F Cravatt; Rémi Martin-Fardon; Fernando Rodríguez de Fonseca; Loren H Parsons Journal: Addict Biol Date: 2018-11-13 Impact factor: 4.280
Authors: Mariana I Holubiec; Juan I Romero; Juan Suárez; Manuel Portavella; Emilio Fernández-Espejo; Eduardo Blanco; Pablo Galeano; Fernando Rodríguez de Fonseca Journal: Psychopharmacology (Berl) Date: 2018-07-29 Impact factor: 4.530
Authors: Laura M Best; Belinda Williams; Bernard Le Foll; Esmaeil Mansouri; Richard P Bazinet; Lin Lin; Vincenzo De Luca; Dina Lagzdins; Pablo Rusjan; Rachel F Tyndale; Alan A Wilson; Christian S Hendershot; Markus Heilig; Sylvain Houle; Junchao Tong; Stephen J Kish; Isabelle Boileau Journal: Neuropsychopharmacology Date: 2020-01-07 Impact factor: 7.853
Authors: Dana Most; Nihal A Salem; Gayatri R Tiwari; Yuri A Blednov; R Dayne Mayfield; R Adron Harris Journal: Addict Biol Date: 2018-04-17 Impact factor: 4.280